AI for Pharma Growth
E194: The Digital Twin Revolution: Reimagining Clinical Trials
AI for Pharma Growth
•December 3, 2025•30 min
0
AI for Pharma Growth•Dec 3, 2025
Key Takeaways
- •Digital twins generate realistic patient trajectories for trial simulations.
- •PROCOVA integrates twins to reduce variability and increase trial power.
- •CNS indications like Alzheimer’s and Parkinson’s lead early adoption.
- •Data harmonization across trials, registries, and EHR is major challenge.
- •Validations use held‑out clinical trial data to ensure predictive accuracy.
Pulse Analysis
The episode opens by defining digital twins as real‑time, virtual replicas of patients that can model disease progression, genetics, and environmental factors. By feeding these high‑fidelity simulations into trial design, researchers can test hypotheses, optimize protocols, and predict outcomes before enrolling a single human subject. This AI‑driven approach promises to cut recruitment bottlenecks, lower the financial risk of late‑stage failures, and accelerate the delivery of life‑saving therapies—key concerns for biopharma executives seeking more efficient development pipelines.
Host Dr. Andre Bates and Unlearn.ai founder Aaron Smith dive into the technical backbone of these twins. Their generative, time‑series models learn from heterogeneous data—clinical trial control arms, registries, and curated electronic health records—to produce statistically realistic patient trajectories. The duo highlights PROCOVA, a prognostic covariate adjustment method that merges twin predictions with traditional randomized control trial data, reducing outcome variability and boosting statistical power without bias. Building such models is hampered by data harmonization challenges: disparate sources, missing values, and subtle context effects like placebo or open‑label biases must be explicitly encoded to achieve reliable performance. Early successes are concentrated in central nervous system disorders—Alzheimer’s, ALS, Parkinson’s—where rich longitudinal datasets exist.
Looking ahead, the speakers predict a rapid inflection point once a digital‑twin‑enhanced trial demonstrates a tangible reduction in sample size or time‑to‑market, likely shaving months off phase‑three timelines. Wider industry adoption will hinge on robust validation against held‑out trial data and clear regulatory pathways. When fully integrated, digital twins could transform trial architecture, enabling precise subgroup identification, adaptive designs, and ultimately a shift from trial‑and‑error to data‑driven certainty in drug development.
Episode Description
In this episode, we explore one of the most disruptive advancements currently reshaping the pharmaceutical and biotech industry: AI-powered digital twins for clinical trials.
Our guest, Aaron Smith, PhD — Founder and Head of Machine Learning at Unlearn.AI — breaks down how digital twins and generative AI are transforming drug development by enabling faster, smaller, and more efficient clinical trials.
Unlearn.AI builds digital twin models: virtual patient replicas created using clinical trial data, registry data, and real-world data. These digital twins allow researchers to simulate how a patient’s disease will progress under standard care, long before a clinical trial is completed. When combined with randomized controlled trials, this technology reduces data variability, increases trial power, and can dramatically shrink sample sizes and timelines.
Some pharma companies are already estimating a six-month reduction in time-to-market, with millions saved in development and operational costs.
What You’ll Learn
What digital twins are and how they simulate patient outcomes using real-world clinical data.
How AI is enabling smaller Phase III trials without sacrificing statistical power.
Why digital twins are helping pharma identify which patients are most likely to benefit from specific treatments.
The biggest barriers to adopting AI in drug development (hint: it’s not the regulators — it’s culture).
Trends shaping the future of clinical trials and precision medicine over the next 10 years.
Digital twins reduce variability and increase power by predicting how each patient would progress under standard care.
The approach (called Prognostic Covariate Adjustment / ProCova) can be used in traditional randomized controlled trials.
Pharma partners expect significant reductions in trial timelines and costs.
AI enables precision trial design by identifying the most prognostic patient features and outcome measures.
About the Podcast
AI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.
This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.
AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.
As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.
This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so...
Show Notes
0
Comments
Want to join the conversation?
Loading comments...